If you want to know Bionaturis Group latest news, here you are our May Newsletter

Imagen Bionaturis Newsletter

IN THIS ISSUE

    • Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

 

    • Biobide presents two scientific posters in SETAC Europe

 

  • Bionaturis Group reports Financial Results and Corporate Update for the Year Ended December 31, 2016

Let’s get to know…

Izaskun Gonzalez de Obieta, 25 years old, born in Bilbao. Degree in Biology by The Basque Country University and Aquaculture by Mutriku High School.

 

 

Izaskun Gonzalez

  • -When you were a child, what did you want to be as an adult?
  • A painter, although I have never been good at painting.
  • -What do you like the most about your job?
  • I always come back home after learning new things.
  • -What are your future challenges?
  • Continue working in something I love and makes me going to work happy and motivated.
  • -Your favourite dish
  • Everyone with rice as main ingredient.
  • -A place
  • The North Gulf, in Barrika.
  • -A film
  • “Hocus Pocus”, by Kenny Ortega.
  • -A historical figure
  • Charles Darwin.
  • -A book
  • Everyone about Harry Potter.
  • -A song
  • “Will you be there”, by Michael Jackson (from the film “Free Willy”).
  • -What do you usually do in your free time?
  • Reading and planning trips (to turn them into reality, of course).
  • -You can’t live without…
  • My cat.
  • -How do you imagine the world in 20 years?
  • I would like it will be more respectful to nature and environment and we will stop wiping flora and fauna out, although I think it is difficult.
  Izaskun has been working as a Lab and Animal Facility Technician in Biobide (Bionaturis Group) since July, 2015.

Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis lead vaccine (BNT005) with the company Laboratorio Biologico de Tandil (Biotandil) for Argentina and Paraguay as the Territory. According to the terms of the license, Biotandil will be responsible for the manufacturing, development, registration, and commercialization of the vaccine in the territory. In exchange Bionaturis will receive 50% of the profits resulting of the commercialization […] Read more

Biobide presents two scientific posters in SETAC Europe

Bionaturis Group company specialized in the use of zebrafish as animal model, Biobide, has an outstanding presence once again in the European annual meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe), held in Brussels (Belgium) from 7-11, May. In this occasion, Biobide will have a booth (No. 49) and present two scientific posters (TU058 y TH049) […] Read more

Bionaturis Group reports Financial Results and Corporate Update for the Year Ended December 31, 2016

Bionaturis Group (ticker BNT), a biotechnology group offering premium solutions for human and animal health, has reported financial results for the Year Ended December 31, 2016 and has provided an update on the Company’s recent developments. According to the global B2B business model of the Group, based on the 4Ps –Products, Portfolio, Platforms and Partnering- it is relevant to note the development portfolio and the license and strategic agreements with third parties as well […] Read more

INVESTOR INFO

Relevant info: information about corporate management. Board agreement of new Internal Code of Conduct (Only in Spanish) (05/05/2017 17.38h) Internal Code of Conduct (Only in Spanish)

Financial Information 2016. 2016 Annual Report (only in Spanish) (28/4/2017 19.45h)

Relevant info. R&D, results, licenses, patents and products. BNT005 license agreement for Argentina and Paraguay (24/4/2017 17.50h)

 

Hi, this newsletter contains information about my website. For any question, please contact to info@bionaturis.com
Imagen Boletín Bionaturis Imagen Twitter Bionaturis Imagen Linked In Bionaturis Imagen Flickr Bionaturis Imagen Youtube Bionaturis Imagen Blog Bionaturis

 

Este e-mail ha sido enviado por *|EMAIL|*¿Por qué me sale esto?    No quiero seguir recibiendo este newsletter    Actualizar las preferencias de suscripción*|LIST:ADDRESSLINE|**|REWARDS|*